Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by barmac6on Feb 07, 2011 12:52pm

227 Views

Post# 18087519

RE: CONEXPO-CON/AGG 2011

Hemisphere GPS

Booth(s): H-31418

+23

Hemisphere GPS Earthworks X200
(Green Product)

Earthworks X200™, Hemisphere GPS’ grade control guidance system, is a 2D solution which is ideal for applications such as trenching, custom profiles, digging basements, blind cuts, single/dual slopes and layering. The system ensures accurate grade control for nearly all types and sizes of excavators. Productivity savings can be as high as 30 - 50% depending on the application. Visit www.hemispheregps.com to see a video of the X200 in action.

Bullboard Posts

B2Gold stock buckles under news of labour strike in Mali